HeMemics Biotechnologies, Inc.
HeMemics Biotechnologies develops a monolayer-graphene biosensor platform (FAST™, HemChip®, HemBox™, ESAP™) for rapid, multiplexed point-of-care detection of antibodies, antigens, and small molecules, selling hardware and disposable chips to healthcare, biodefense, agriculture, and life-sciences research customers.
- Company typePrivate
- Founded2017
- HeadquartersGaithersburg, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What HeMemics Biotechnologies, Inc. does
Hememics Biotechnologies is a Gaithersburg, Maryland-based privately held company that develops a proprietary point-of-care diagnostic platform built on monolayer graphene biosensor technology using impedance spectroscopy. The platform enables rapid, multiplexed detection of antibodies, antigens, and small-molecule targets in a portable form factor, targeting gaps left by conventional ELISA workflows (2–24 hour assay time, $95–$1,200+ kit cost, $3,000–$50,000+ reader cost, requirement for enzymes and secondary antibodies). The core commercial offering is a hardware-plus-consumables system: the FAST™ immunoassay platform pairs disposable 96-well plates (priced at $20 per kit) with a portable digital reader ($1,500), delivering antibody–antigen binding results in under one hour; the HemChip® extends this to a single-use biochip with 32 individually programmed sensors, read by the HemBox™ portable reader in approximately five minutes with Bluetooth data transmission; and ESAP™ is a graphene-based protein-validation workflow oriented at the antibody-reproducibility problem in life sciences research.
The company pursues a sales-led, event-driven go-to-market targeting healthcare/point-of-care diagnostics (primary segment), biodefense and military (biotoxin detection), agriculture (herbicide/pesticide residue testing), drugs-of-abuse testing, and life-sciences research. Its revenue mechanics combine one-time hardware sales (HemBox readers) with recurring consumable pull-through (HemChip and FAST plates) and early-stage commercial trial agreements. Public pricing is disclosed only for FAST™ components; HemChip and HemBox pricing remain undisclosed. The company has received non-dilutive government support (HHS/BARDA, 2020, for COVID-19 antigen/antibody diagnostics) and has progressed from Inova Personalized Health Accelerator acceptance (2017) through multiple seed financings (~$4.75M disclosed across AMVI Partners in 2019 and TEDCO-led rounds in 2023 and 2025) to its first named commercial customer validation (KanPro Research, December 2025). Headcount is reported at 1–10, consistent with an early commercial-deployment phase.
Leadership combines serial technology entrepreneurs (Chairman/CEO John L. Warden Jr., founder of General Graphene's James Vig Sherrill) with domain scientific authority (Founder/President/CSO Dr. David Ho, a platelet/cell-preservation researcher) and is supplemented by a Director of R&D (Srivatsa Aithal, ex-Abnova Taiwan) and a Director of Investor Relations (Valerie Vo). Operations are single-country (USA), with manufacturing scale enabled by a 2023 strategic partnership with General Graphene Corporation for cost-effective graphene production.
HeMemics Biotechnologies, Inc. firmographics
Firmographics- Name
- HeMemics Biotechnologies, Inc.
- Legal name
- Hememics Biotechnologies, Inc.
- Website
- https://hememics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- HeMemics Biotechnologies develops a monolayer-graphene biosensor platform (FAST™, HemChip®, HemBox™, ESAP™) for rapid, multiplexed point-of-care detection of antibodies, antigens, and small molecules, selling hardware and disposable chips to healthcare, biodefense, agriculture, and life-sciences research customers.
- Ownership category
- akta.pro rank
HeMemics Biotechnologies, Inc. industry classification
Industry- Product category
- Point-of-care biosensor diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industries
- Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where HeMemics Biotechnologies, Inc. is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
HeMemics Biotechnologies, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Hardware Sales: Sale of portable reader devices (HemBox™) to healthcare facilities, laboratories, and defense clients. The reader is a one-time capital purchase.
- Consumables (Disposable Chips): Recurring revenue from sale of disposable biochips (HemChip®, FAST™ plates) that are single-use per test. Each test requires a new chip.
- Commercial Trial Agreements: Early-stage commercial trials and validation agreements with research organizations like KanPro Research for the ESAP™ platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | FAST™ Kit - $20 per kit |
| One time/ perpetual license | Multi-year contract | FAST™ Reader - $1,500 |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
HeMemics Biotechnologies, Inc. product offering
Product offeringCore offering
Hememics sells a graphene-based point-of-care biosensor platform comprising the FAST™ immunoassay screening system, HemChip® disposable biochips with 32 sensors per chip, and the HemBox™ portable Bluetooth reader, which together detect antibodies, antigens, and small molecule targets simultaneously with results delivered in 5 minutes. The ESAP™ platform extends the technology into protein validation workflows for life sciences research. Customers are healthcare providers, life sciences researchers, biodefense agencies, agriculture testers, and drugs-of-abuse testing operators.
Product overview
HeMemics Biotechnologies offers a platform-plus-modules architecture centered around graphene-based biosensor technology. The core FAST™ platform combines with HemChip® disposable biochips (32 sensors per chip) and the HemBox™ portable reader to deliver multiplexed detection of antibodies, antigens, and molecular targets. ESAP™ represents their validated platform for antibody reproducibility testing. The portfolio spans point-of-care diagnostics, biodefense, agriculture testing, drugs of abuse detection, and healthcare applications.
Differentiator
Problem solved
Functional benefit
Products and services
- FAST™ (Functionalized Analyte Screening Technology) FAST™ is an immunoassay-based antibody-antigen screening platform that delivers binding results in under one hour using low-cost polymer-based disposable 96-well plates with digital endpoint output, designed to replace slower, more expensive ELISA workflows for life sciences researchers and clinical laboratories.
- HemChip® HemChip® is a single-use biochip integrating 32 individually programmed graphene sensors that detect small molecule, molecular, and antigen targets simultaneously, paired with the HemBox™ reader to deliver results in 5 minutes for point-of-care, biodefense, agriculture, and drugs-of-abuse testing applications.
- HemBox™ HemBox™ is a portable Bluetooth-enabled reader device that interprets signals from HemChip® disposable biochips and delivers multiplexed detection results in 5 minutes, enabling field and point-of-care use without specialized training.
- ESAP™ ESAP™ is a graphene-based protein validation platform that delivers faster, cheaper, and more objective antibody-antigen binding results for life sciences research organizations combating the antibody-reproducibility crisis in biologics development.
Quantifiable outcome
- 5-minute diagnostic results vs 2-24 hours for ELISA
- +3 more outcomes
Companies that use HeMemics Biotechnologies, Inc.
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles5 records
HeMemics Biotechnologies, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
HeMemics Biotechnologies, Inc. partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- KanPro ResearchflagshipKanPro Research validated Hememics' ESAP™ platform for antibody-antigen binding analysis. The validation resulted in KanPro placing a commercial trial order, representing the first commercial customer validation of the platform to address the antibody-reproducibility crisis.
- General Graphene CorporationcoreStrategic partnership for large-scale production of graphene-based biosensors. General Graphene, founded by board member James Vig Sherrill, provides cost-effective graphene manufacturing capabilities. This partnership enables Hememics to scale production of its biosensor platforms for commercialization.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
HeMemics Biotechnologies, Inc. competitors and assessment
Company assessmentDirect peers
- Meso Scale Diagnostics: Privately held leader in multiplexed ECL-based immunoassays for biomarker and biodefense detection. Closest technology analogue to Hememics' FAST™/HemChip® multiplexing approach and overlapping customer base in life-sciences research.
- Carterra: High-throughput SPR-based antibody screening and characterization platform. Directly comparable to Hememics' ESAP™ value proposition of accelerating antibody-antigen binding workflows in biologics development.
- Gator Bio: Label-free BLI biosensor instruments for antibody kinetics and protein interaction analysis. Comparable to Hememics' impedance-based biosensor approach in the life-sciences research market.
- Chembio Diagnostics: Small-cap POC diagnostics company (lateral flow and DPP platform) focused on infectious disease, drugs of abuse, and biodefense. Closest size-stage comparable pursuing overlapping POC and biodefense use cases.
Broad incumbents
- Bio-Rad Laboratories: Established ELISA kit and reader manufacturer with broad life-sciences and clinical diagnostics portfolio. Represents the incumbent benchmark Hememics is pricing against ($95–$1.2k+ kits, $3k–$50k+ readers).
- Thermo Fisher Scientific: Largest life-sciences tools and diagnostics company, with ELISA, immunoassay, and biosensor offerings spanning research and clinical markets. Represents both a competitor and a potential acquirer profile.
- Abbott: Global POC diagnostics leader (i-STAT, Binax, Alinity). Hememics' POC platform would compete against Abbott's installed base and sales channels in hospitals and urgent care.
- Roche Diagnostics: IVD giant (Elecsys, cobas). Comparable electrochemiluminescence immunoassay franchise competes with FAST™ in clinical chemistry and immunoassay menus globally.
- QuidelOrtho: POC rapid diagnostics player (Sofia platform) with growing immunoassay footprint. Direct overlap with Hememics' POC strategy for hospitals and physician offices.
- Siemens Healthineers: Large IVD franchise (Atellica, ADVIA Centaur) covering immunoassays and clinical chemistry. Represents the deep-pocketed incumbent Hememics would need to displace to scale in hospital labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
HeMemics Biotechnologies, Inc. social profiles
Digital presenceHeMemics Biotechnologies, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
HeMemics Biotechnologies, Inc. leadership team
Management profileNumber of profiles
Profiles9 records
HeMemics Biotechnologies, Inc. funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HeMemics Biotechnologies, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HeMemics Biotechnologies, Inc.
What does HeMemics Biotechnologies, Inc. do?
Hememics sells a graphene-based point-of-care biosensor platform comprising the FAST™ immunoassay screening system, HemChip® disposable biochips with 32 sensors per chip, and the HemBox™ portable Bluetooth reader, which together detect antibodies, antigens, and small molecule targets simultaneously with results delivered in 5 minutes. The ESAP™ platform extends the technology into protein validation workflows for life sciences research. Customers are healthcare providers, life sciences researchers, biodefense agencies, agriculture testers, and drugs-of-abuse testing operators.
Is HeMemics Biotechnologies, Inc. a public or private company?
HeMemics Biotechnologies, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was HeMemics Biotechnologies, Inc. founded?
HeMemics Biotechnologies, Inc. was founded in 2017. It employs 1 to 10 people.
Where is HeMemics Biotechnologies, Inc. based?
HeMemics Biotechnologies, Inc. is headquartered in Gaithersburg, United States, in the North America region.
How does HeMemics Biotechnologies, Inc. make money?
Three revenue lines are on record. Hardware Sales are the primary driver. The others are consumables (Disposable Chips) and commercial Trial Agreements.
Who are HeMemics Biotechnologies, Inc.'s main competitors?
Direct peers on record are Meso Scale Diagnostics, Carterra, Gator Bio and Chembio Diagnostics. Broad incumbents are Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott, Roche Diagnostics, QuidelOrtho and Siemens Healthineers.
Does HeMemics Biotechnologies, Inc. have an API?
No public API is recorded for HeMemics Biotechnologies, Inc..
What industry is HeMemics Biotechnologies, Inc. in?
HeMemics Biotechnologies, Inc.'s product category is Point-of-care biosensor diagnostics. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAAALAH, Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing). Its NAICS code is 334516 and its SIC code is 3826.